• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Medical Device Market
    Medical Device News
    Medical Device Stocks
    • Medical Device Market
    • Medical Device News
    • Medical Device Stocks
    medical device investing

    HTG Announces New Australian Patent for Its Technology

    Gabrielle Lakusta
    Feb. 26, 2018 04:23PM PST
    Medical Device Investing

    HTG Molecular Diagnostics (Nasdaq:HTGM), a provider of instruments, reagents, and services for molecular profiling applications, today announced the issuance of Australian Patent Number 2012316129 for “Methods of Co-detecting mRNA and Small Non-coding RNA.” As quoted in the press release: “We are pleased to strengthen our intellectual property protection with the addition of this Australian patent …

    HTG Molecular Diagnostics (Nasdaq:HTGM), a provider of instruments, reagents, and services for molecular profiling applications, today announced the issuance of Australian Patent Number 2012316129 for “Methods of Co-detecting mRNA and Small Non-coding RNA.”

    As quoted in the press release:

    “We are pleased to strengthen our intellectual property protection with the addition of this Australian patent covering this application of our core technology,” stated TJ Johnson, Chief Executive Officer of HTG. “We believe miRNAs are gaining relevance as possible diagnostic markers and are very pleased to have our methods of mRNA and miRNA co-detection patented in multiple geographies. We have consistently sought to protect uses of our technology in the U.S. and globally, and now have over 20 patents covering our nuclease-protection-based technologies, including our HTG EdgeSeq method.”

    Click here to read the full press release.

    molecular diagnosticsmedical device investinghtg molecular diagnostics
    The Conversation (0)

    Go Deeper

    AI Powered
    Senior woman doing exercises alongside closeup of DNA.

    5 US Longevity and Anti-aging Stocks to Watch in 2025

    Test tubes.

    Biotech Market Forecast: Top Trends for Biotech in 2025

    Latest News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Medical Device Investing Stocks

    Cardiex Limited

    CDX:AU
    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    ×